This site is intended for a US audience Non-US Residents For Patients and Caregivers

Patients with Inoperable CTEPH

In a 2011 registry of 679 CTEPH patients, 37% (247) were deemed inoperable1

According to the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension2:

  • All patients diagnosed with CTEPH should receive lifelong anticoagulation
  • Operability is based on team experience, accessibility of pulmonary artery (PA) lesions, correlation between severity of pulmonary hypertension (PH) and degree of PA obstructions, and comorbidities
noperable CTEPH patients table

Operability is determined by considerations that are multifactorial, complex, and dependent on center expertise, so reevaluation of operability by a second experienced CTEPH center in cases initially deemed inoperable is recommended.2

 

Patients deemed inoperable should be evaluated for approved medical therapy or balloon pulmonary angioplasty (BPA) with or without approved medical therapy.2,3

Nonsurgical Treatment of CTEPH

Hear about the ways to treat CTEPH when surgery is not an option.

Compensated by Bayer for video.

Learn about treating recurrent CTEPH

References:

1. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-1981. 2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. 3. Kim NH, D'Armini AM, Delcroix M, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024;64(4):2401294.

BAYER and the Bayer Cross are registered trademarks of Bayer. All other trademarks are property of their respective owners. These trademark owners are not affiliated with Bayer and do not sponsor or endorse Bayer.

 

Site last modified 06/2025

© 2025 Bayer. All rights reserved.